CVE:MBI

Med Biogene Competitors

C$0.04
-0.01 (-18.18 %)
(As of 10/3/2019)
Add
Compare
Today's Range
C$0.05
Now: C$0.05
C$0.05
50-Day Range
C$0.05
MA: C$0.04
C$0.05
52-Week Range
C$0.02
Now: C$0.05
C$0.08
Volume2,000 shs
Average Volume29,135 shs
Market CapitalizationC$596,610.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Med Biogene (CVE:MBI) Vs. AKU, LXG, SQD, SVA, GEN, and LMD

Should you be buying MBI stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Med Biogene, including Akumin (AKU), LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), and LED Medical Diagnostics (LMD).

Med Biogene (CVE:MBI) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Med Biogene and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Med BiogeneN/AN/AN/A
AkuminN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Med Biogene and Akumin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Med Biogene0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, suggesting a potential upside of 7.59%. Given Akumin's higher possible upside, analysts clearly believe Akumin is more favorable than Med Biogene.

Earnings & Valuation

This table compares Med Biogene and Akumin's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Med BiogeneN/AN/AN/AC($0.01)-7.50
AkuminC$246.08 million1.11C$-25,263,475.00C($0.37)-10.82

Med Biogene has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than Med Biogene, indicating that it is currently the more affordable of the two stocks.

Summary

Akumin beats Med Biogene on 3 of the 5 factors compared between the two stocks.

Med Biogene (CVE:MBI) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares Med Biogene and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Med BiogeneN/AN/AN/A
LexaGeneN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Med Biogene and LexaGene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Med Biogene0000N/A
LexaGene0000N/A

Valuation & Earnings

This table compares Med Biogene and LexaGene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Med BiogeneN/AN/AN/AC($0.01)-7.50
LexaGeneN/AN/AN/AC($0.12)-6.30

Med Biogene is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Med Biogene (CVE:MBI) and SQI Diagnostics (CVE:SQD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for Med Biogene and SQI Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Med Biogene0000N/A
SQI Diagnostics0000N/A

Profitability

This table compares Med Biogene and SQI Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Med BiogeneN/AN/AN/A
SQI DiagnosticsN/AN/AN/A

Earnings and Valuation

This table compares Med Biogene and SQI Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Med BiogeneN/AN/AN/AC($0.01)-7.50
SQI DiagnosticsC$977,000.00122.05C$-12,264,984.00C($0.04)-9.72

Med Biogene has higher earnings, but lower revenue than SQI Diagnostics. SQI Diagnostics is trading at a lower price-to-earnings ratio than Med Biogene, indicating that it is currently the more affordable of the two stocks.

Summary

Med Biogene beats SQI Diagnostics on 2 of the 3 factors compared between the two stocks.

Sernova (CVE:SVA) and Med Biogene (CVE:MBI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Earnings & Valuation

This table compares Sernova and Med Biogene's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/AN/AC($0.03)-56.30
Med BiogeneN/AN/AN/AC($0.01)-7.50

Sernova is trading at a lower price-to-earnings ratio than Med Biogene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sernova and Med Biogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/AN/AN/A
Med BiogeneN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Sernova and Med Biogene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
Med Biogene0000N/A

Summary

Med Biogene beats Sernova on 2 of the 2 factors compared between the two stocks.

Med Biogene (CVE:MBI) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Med Biogene and GeneNews, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Med Biogene0000N/A
GeneNews0000N/A

Profitability

This table compares Med Biogene and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Med BiogeneN/AN/AN/A
GeneNewsN/AN/AN/A

Valuation and Earnings

This table compares Med Biogene and GeneNews' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Med BiogeneN/AN/AN/AC($0.01)-7.50
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

Med Biogene has higher earnings, but lower revenue than GeneNews. Med Biogene is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Summary

GeneNews beats Med Biogene on 2 of the 3 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and Med Biogene (CVE:MBI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for LED Medical Diagnostics and Med Biogene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LED Medical Diagnostics0000N/A
Med Biogene0000N/A

Earnings & Valuation

This table compares LED Medical Diagnostics and Med Biogene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26
Med BiogeneN/AN/AN/AC($0.01)-7.50

Med Biogene has lower revenue, but higher earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than Med Biogene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LED Medical Diagnostics and Med Biogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LED Medical DiagnosticsN/AN/AN/A
Med BiogeneN/AN/AN/A

Summary

Med Biogene beats LED Medical Diagnostics on 2 of the 3 factors compared between the two stocks.


Med Biogene Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.7$3.95-1.5%C$273.40 millionC$246.08 million-10.82
LXG
LexaGene
0.5$0.75-12.0%C$83.27 millionN/A-6.30News Coverage
Gap Up
SQD
SQI Diagnostics
0.9$0.35-0.0%C$52.59 millionC$977,000.00-9.72
SVA
Sernova
0.5$1.52-2.6%C$31.35 millionN/A-56.30News Coverage
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40-100.0%C$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.51-3.9%C$5.58 millionC$37,517.00-15.45
IDL
Imaging Dynamics
0.4$0.07-7.7%C$4.13 millionC$378,253.00-3.42
DXD
3D Signatures
0.5$0.04-100.0%C$2.66 millionN/A-0.91Gap Down
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.